solid tumor Archives | Be Korea-savvy

Home / Posts tagged solid tumor

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Lugano, Switzerland, Jan. 12 (Korea Bizwire)– Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities. TAS0953/HM06 is an investigational oral treatment which inhibits several [...]

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101

NEW YORK, Sept. 25 (Korea Bizwire) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday [...]

RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA™ in Advanced Solid Tumors

TEL-AVIV, Israel, Jun. 21 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced positive final results from the Phase I study with YELIVA™ (ABC294640) in advanced [...]